Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 15
2004 4
2005 8
2006 6
2007 10
2008 8
2009 8
2010 7
2011 11
2012 9
2013 19
2014 15
2015 18
2016 11
2017 9
2018 10
2019 16
2020 17
2021 20
2022 7
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Results by year

Filters applied: . Clear all
Page 1
Effects of resistance training intensity on muscle quantity/quality in middle-aged and older people: a randomized controlled trial.
Otsuka Y, Yamada Y, Maeda A, Izumo T, Rogi T, Shibata H, Fukuda M, Arimitsu T, Miyamoto N, Hashimoto T. Otsuka Y, et al. Among authors: shibata h. J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):894-908. doi: 10.1002/jcsm.12941. Epub 2022 Feb 20. J Cachexia Sarcopenia Muscle. 2022. PMID: 35187867 Free PMC article. Clinical Trial.
Crucial role of iron in epigenetic rewriting during adipocyte differentiation mediated by JMJD1A and TET2 activity.
Suzuki T, Komatsu T, Shibata H, Tanioka A, Vargas D, Kawabata-Iwakawa R, Miura F, Masuda S, Hayashi M, Tanimura-Inagaki K, Morita S, Kohmaru J, Adachi K, Tobo M, Obinata H, Hirayama T, Kimura H, Sakai J, Nagasawa H, Itabashi H, Hatada I, Ito T, Inagaki T. Suzuki T, et al. Among authors: shibata h. Nucleic Acids Res. 2023 Jul 7;51(12):6120-6142. doi: 10.1093/nar/gkad342. Nucleic Acids Res. 2023. PMID: 37158274 Free PMC article.
Sesamin Metabolites Suppress the Induction of Cellular Senescence.
Araki C, Takemoto D, Kitagawa Y, Tateishi N, Rogi T, Izumo T, Kawamoto S, Shibata H, Hara E, Nakai M. Araki C, et al. Among authors: shibata h. Nutrients. 2023 Mar 27;15(7):1627. doi: 10.3390/nu15071627. Nutrients. 2023. PMID: 37049468 Free PMC article.
Cellsorba.
Shibata H, Kuriyama T, Yamawaki N. Shibata H, et al. Ther Apher Dial. 2003 Feb;7(1):44-7. doi: 10.1046/j.1526-0968.2003.00009.x. Ther Apher Dial. 2003. PMID: 12921114
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Shibata H, Aoki T, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kudo M, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Ohama H, et al. Among authors: shibata h. Oncology. 2023;101(9):542-552. doi: 10.1159/000530028. Epub 2023 Aug 8. Oncology. 2023. PMID: 37552968
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Shibata H, Aoki T, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: shibata h. Cancer Med. 2023 Jan;12(1):325-334. doi: 10.1002/cam4.4854. Epub 2022 Jun 3. Cancer Med. 2023. PMID: 35666040 Free PMC article.
The Active Sensing of Control Difference.
Wen W, Shibata H, Ohata R, Yamashita A, Asama H, Imamizu H. Wen W, et al. Among authors: shibata h. iScience. 2020 May 22;23(5):101112. doi: 10.1016/j.isci.2020.101112. Epub 2020 Apr 30. iScience. 2020. PMID: 32408176 Free PMC article.
208 results